|Application ||WB, IHC-P, FC, E|
|Calculated MW||64419 Da|
|Antigen Region||203-231 aa|
|Other Names||Complement factor H-related protein 5, FHR-5, CFHR5, CFHL5, FHR5|
|Target/Specificity||This CFHR5 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 203-231 amino acids from the Central region of human CFHR5.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||CFHR5 Antibody (Center) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Involved in complement regulation. The dimerized forms have avidity for tissue-bound complement fragments and efficiently compete with the physiological complement inhibitor CFH.|
|Tissue Location||Expressed by the liver and secreted in plasma.|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
CFHR5 is a member of a small complement factor H (CFH) gene cluster on chromosome 1. Each member of this gene family contains multiple short consensus repeats (SCRs) typical of regulators of complement activation. The protein encoded by this gene has nine SCRs with the first two repeats having heparin binding properties, a region within repeats 5-7 having heparin binding and C reactive protein binding properties, and the C-terminal repeats being similar to a complement component 3 b (C3b) binding domain. This protein co-localizes with C3, binds C3b in a dose-dependent manner, and is recruited to tissues damaged by C-reactive protein. Allelic variations in this gene have been associated, but not causally linked, with two different forms of kidney disease: membranoproliferative glomerulonephritis type II (MPGNII) and hemolytic uraemic syndrome (HUS). [provided by RefSeq].
McRae, J.L., et al. Genetica 114(2):157-161(2002)
Murphy, B., et al. Am. J. Kidney Dis. 39(1):24-27(2002)
Narkio-Makela, M., et al. Clin. Immunol. 100(1):118-126(2001)
McRae, J.L., et al. J. Biol. Chem. 276(9):6747-6754(2001)
If you have any additional inquiries please email technical services at firstname.lastname@example.org.